J&J Seeks to Revolutionize Maternal Fetal Immunology with Nipocalimab

Johnson & Johnson is making strides in maternal-fetal immunology with its investigational monoclonal antibody, nipocalimab, aimed at treating rare blood disorders in fetuses and newborns. This effort comes more than five decades after the approval of Rh immunoglobulin (RhoGAM), the only other drug in this field that treats Rh-negative pregnancies to prevent hemolytic disease of the fetus and newborn (HDFN). Nipocalimab, which recently received fast-track designation from the FDA, targets fetal and neonatal alloimmune thrombocytopenia (FNAIT), a condition where the pregnant person’s immune system attacks fetal platelets, risking severe bleeding complications for the baby. Unlike current treatments that include intravenous immunoglobulin (IVIG) with or without steroids, nipocalimab offers a targeted approach to prevent maternal alloantibodies from affecting the fetus, showcasing J&J’s commitment to pioneering in an area with significant unmet medical needs. This development underlines the potential of nipocalimab to transform treatment paradigms across a spectrum of autoantibody-driven diseases.

To read more, click here.

[Source: Fierce Biotech, April 2nd, 2024]